Publications by authors named "Carole Sourbier"

45Publications

Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion.

BMC Cancer 2019 Sep 13;19(1):917. Epub 2019 Sep 13.

Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10 - Hatfield CRC, Room 1-5940, Bethesda, MD, 20892, USA.

View Article and Find Full Text PDF
September 2019

Uncoupling tumor-stroma interactions in breast cancer patients.

Semin Oncol 2017 06 18;44(3):235-236. Epub 2017 Oct 18.

Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD. Electronic address:

View Article and Find Full Text PDF
June 2017

Detecting the Potential Pharmacological Synergy of Drug Combination by Viability Assays In Vitro.

Methods Mol Biol 2018 ;1709:129-137

Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

View Article and Find Full Text PDF
July 2018

Protein kinase D inhibitor CRT0066101 suppresses bladder cancer growth in vitro and xenografts via blockade of the cell cycle at G2/M.

Cell Mol Life Sci 2018 03 25;75(5):939-963. Epub 2017 Oct 25.

Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

View Article and Find Full Text PDF
March 2018

Plasma HSP90α and liver cancer: a potential biomarker?

Authors:
Carole Sourbier

EBioMedicine 2017 11 10;25:7-8. Epub 2017 Oct 10.

Urologic Oncology Branch, National Cancer Institute, NIH, Bldg 10, CRC 1W-3961, 9000 Rockville Pike, Bethesda, MD 20892, United States. Electronic address:

View Article and Find Full Text PDF
November 2017

Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model (UOK276).

Genes Chromosomes Cancer 2017 10 24;56(10):719-729. Epub 2017 Jul 24.

Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

View Article and Find Full Text PDF
October 2017

Co-opting a Bioorthogonal Reaction for Oncometabolite Detection.

J Am Chem Soc 2016 12 30;138(49):15813-15816. Epub 2016 Nov 30.

Chemical Biology Laboratory, National Cancer Institute , Frederick, Maryland 21702, United States.

View Article and Find Full Text PDF
December 2016

Synthesis of a stable and orally bioavailable englerin analogue.

Bioorg Med Chem Lett 2016 06 8;26(11):2641-4. Epub 2016 Apr 8.

Department of Chemistry, University of Hawaii at Manoa, 2545 McCarthy Mall, Honolulu, HI 96822, United States; The University of Hawaii Cancer Center, 701 Ilalo Street, Honolulu, HI 96813, United States. Electronic address:

View Article and Find Full Text PDF
June 2016

SnapShot: Renal Cell Carcinoma.

Cancer Cell 2016 Apr;29(4):610-610.e1

Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.

View Article and Find Full Text PDF
April 2016

Lack of mitochondrial topoisomerase I (TOP1mt) impairs liver regeneration.

Proc Natl Acad Sci U S A 2015 Sep 24;112(36):11282-7. Epub 2015 Aug 24.

Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892;

View Article and Find Full Text PDF
September 2015

Tonantzitlolone cytotoxicity toward renal cancer cells is PKCθ- and HSF1-dependent.

Oncotarget 2015 Oct;6(30):29963-74

Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.

View Article and Find Full Text PDF
October 2015

Metabolism and oxidative stress response pathways in kidney cancer: a tale of chance and necessity.

Am Soc Clin Oncol Educ Book 2015 :220-5

From the Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute at the National Institutes of Health, Bethesda, MD.

View Article and Find Full Text PDF
February 2016

New strategies in renal cell carcinoma: targeting the genetic and metabolic basis of disease.

Clin Cancer Res 2015 Jan;21(1):10-7

Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.

View Article and Find Full Text PDF
January 2015

Mitochondrial topoisomerase I (top1mt) is a novel limiting factor of doxorubicin cardiotoxicity.

Clin Cancer Res 2014 Sep 8;20(18):4873-81. Epub 2014 Apr 8.

Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology;

View Article and Find Full Text PDF
September 2014

The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models.

Cancer Res 2013 Dec 11;73(23):7022-33. Epub 2013 Oct 11.

Authors' Affiliations: Urologic Oncology Branch and Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland; Departments of Urology, Biochemistry, and Molecular Biology, Cancer Research Institute, SUNY Upstate Medical University, Syracuse, New York; and Department of Urology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.

View Article and Find Full Text PDF
December 2013

Metabolic reprogramming for producing energy and reducing power in fumarate hydratase null cells from hereditary leiomyomatosis renal cell carcinoma.

PLoS One 2013 15;8(8):e72179. Epub 2013 Aug 15.

Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.

View Article and Find Full Text PDF
September 2014

Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma.

PLoS One 2013 14;8(2):e56083. Epub 2013 Feb 14.

Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health & Human Development, National Institutes of Health, Bethesda, Maryland, United States of America.

View Article and Find Full Text PDF
August 2013

Mitochondrial topoisomerase I is critical for mitochondrial integrity and cellular energy metabolism.

PLoS One 2012 20;7(7):e41094. Epub 2012 Jul 20.

Laboratory of Molecular Pharmacology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.

View Article and Find Full Text PDF
April 2013

Ovarian cancer: emerging molecular-targeted therapies.

Authors:
Carole Sourbier

Biologics 2012 20;6:147-54. Epub 2012 Jun 20.

Rockville, MD, USA.

View Article and Find Full Text PDF
October 2012

Characterization of two mouse models of metastatic pheochromocytoma using bioluminescence imaging.

Cancer Lett 2012 Mar 20;316(1):46-52. Epub 2011 Oct 20.

Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD 20892-1109, USA.

View Article and Find Full Text PDF
March 2012

Met and the microenvironment: new insights for ovarian cancer metastasis.

Authors:
Carole Sourbier

Cell Adh Migr 2011 May-Jun;5(3):209-10. Epub 2011 May 1.

Urologic Oncology Branch, National Cancer Institute, Bethesda, MD, USA.

View Article and Find Full Text PDF
December 2011

Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma.

Cell Cycle 2010 Oct 27;9(20):4183-9. Epub 2010 Oct 27.

Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article and Find Full Text PDF
October 2010

Role of the RNA-binding protein HuR in human renal cell carcinoma.

Carcinogenesis 2010 Jun 10;31(6):1018-26. Epub 2010 Mar 10.

Institut National de la Sante et de la Recherche Medicale U682, Section of Renal Cancer and Physiopathology, University de Strasbourg, School of Medicine, Strasbourg, 67085 France.

View Article and Find Full Text PDF
June 2010

von Hippel-Lindau tumor suppressor gene-dependent mRNA stabilization of the survival factor parathyroid hormone-related protein in human renal cell carcinoma by the RNA-binding protein HuR.

Carcinogenesis 2009 Mar 4;30(3):387-96. Epub 2008 Dec 4.

Institut National de la Santé et de la Recherche Médicale U727, Section of Renal Pharmacology and Physiopathology, School of Medicine, University Louis Pasteur, Strasbourg, France.

View Article and Find Full Text PDF
March 2009

Targeting the nuclear factor-kappaB rescue pathway has promising future in human renal cell carcinoma therapy.

Cancer Res 2007 Dec;67(24):11668-76

Institut National de la Sante et de la Recherche Medicale U727, Section of Renal Pharmacology and Physiopathology, University Louis Pasteur, School of Medicine, Strasbourg, France.

View Article and Find Full Text PDF
December 2007

The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy.

Cancer Res 2006 May;66(10):5130-42

Institut National de la Sante et de la Recherche Medicale U727, University Louis Pasteur School of Medicine and Departments of Pathology and Urology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

View Article and Find Full Text PDF
May 2006

Parathyroid hormone-related protein in human renal cell carcinoma.

Cancer Lett 2006 Aug 11;240(2):170-82. Epub 2005 Oct 11.

INSERM U727, Section of Renal Pharmacology and Physiopathology, School of Medicine, University Louis Pasteur, 67085 Strasbourg, France.

View Article and Find Full Text PDF
August 2006

Antitumor effect of parathyroid hormone-related protein neutralizing antibody in human renal cell carcinoma in vitro and in vivo.

Carcinogenesis 2006 Jan 4;27(1):73-83. Epub 2005 Aug 4.

INSERM U727, Section of Renal Pharmacology and Physiopathology, University Louis Pasteur, School of Medicine, and Department of Pathology, Hôpitaux Universitaires de Strasbourg, Strasbourg, 67091 France.

View Article and Find Full Text PDF
January 2006